How to Navigate the Narcolepsy Pharmacotherapy Landscape

By Sree Roy In the increasingly verdant landscape of narcolepsy pharmacotherapy, no two drugs fill the same space.  The variety of narcolepsy drugs available in the United States work through different mechanisms—GABA, histamine, and perhaps soon orexin, as well as other systems. The drugs treat narcolepsy symptoms—such as excessive daytime sleepiness and cataplexy—to differing degrees,…

Read More

O Me of Little Faith

Man is a creature who hardly knows himself. “The heart is deceitful above all things, and desperately sick; who can understand it?” (Jeremiah 17:9). Even as a Christian with a new heart, I continue to discover within myself new contradictions, fresh perplexities, strange paradoxes. Take, for example, the cohabitation of a desire for a sturdier…

Read More

Incannex Taps Fortrea to Manage Phase 2/3 Trial for Sleep Apnea Drug Candidate

Incannex Healthcare Ltd, a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies, has engaged Fortrea as the contract research organization to manage the Investigational New Drug opening phase 2/3 clinical trial investigating IHL-42X for the treatment of obstructive sleep apnea. The phase 2/3 clinical trial will assess the safety and efficacy…

Read More

Sleep Deprivation Benefited Our Ancestors, Yet Harms Us Now—But Staying Fit May Help Us Cope

By Madhura Lotlikar, McGill University Humans need less sleep than our closest evolutionary relatives. However, we often sleep less than we need. Needing less sleep is a consequence of our ancestors’ choices to remain awake longer — a behaviour that led to evolutionary benefits. Sleeping less than we need is the result of our modern-day…

Read More